GHRP-2 (10mg Vial) Dosage Protocol

GHRP-2 (10 mg Vial) Dosage Protocol

Quickstart Highlights

GHRP-2 dosage protocols leverage this potent synthetic hexapeptide (pralmorelin) that stimulates growth hormone (GH) release by acting as a ghrelin receptor agonist in the pituitary and hypothalamus[1][2]. Researchers and clinicians have explored GHRP-2 as a diagnostic GH stimulant and investigated its potential for supporting healthy GH secretion patterns, lean body composition, recovery, and sleep quality[3][4]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
  • Typical daily range: 100–300 mcg once daily (gradual titration).
  • Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U‑100 insulin syringe.
  • Timing: Bedtime administration aligns with natural nocturnal GH secretion[5]; empty stomach preferred.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days[6][7].
GHRP-2 Vial

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 100 mcg 3 units (0.03 mL)
Weeks 3–4 150 mcg 4.5 units (0.045 mL)
Weeks 5–8 200 mcg 6 units (0.06 mL)
Weeks 9–12 250–300 mcg 7.5–9 units (0.075–0.09 mL)

Frequency: Inject once daily subcutaneously at bedtime on an empty stomach (at least 2–3 hours after the last meal) to maximize the GH pulse[5]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 28 days[8].

Advanced / Multiple Daily Dosing (Experienced Research Use Only)

In research settings exploring enhanced GH release, protocols have used 2–3 injections per day[4]. Be aware that chronic high-frequency stimulation can lead to receptor desensitization (tachyphylaxis)[9][10].

Phase Dose per Injection (mcg) Frequency Units (per injection) (mL)
Phase 1 (Weeks 1–2) 100 mcg Twice daily 3 units (0.03 mL)
Phase 2 (Weeks 3–4) 150 mcg Twice daily 4.5 units (0.045 mL)
Phase 3 (Weeks 5–8) 200 mcg 2–3× daily 6 units (0.06 mL)

A “5 days on / 2 days off” cycle is often suggested to help restore receptor sensitivity[9]. Even with breaks, be mindful that chronic stimulation can attenuate the GH response over time.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration (once‑daily regimen).

  • Peptide Vials (GHRP-2, 10 mg each):

    • 8 weeks ≈ 1 vial (~9.1 mg total usage)
    • 12 weeks ≈ 2 vials (~15–16 mg total)
    • 16 weeks ≈ 3 vials (~22–23 mg total)
  • Insulin Syringes (U‑100, 0.3 mL or 0.5 mL recommended):

    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

    • 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
    • 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
    • 16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
GHRP-2 Vial
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Support pulsatile GH release for research into body composition, recovery, and sleep quality[4].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 100–300 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

  • Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated.
  • Target: 200–300 mcg daily by Weeks 5–12.
  • Frequency: Once per day (subcutaneous) at bedtime.
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Bedtime on an empty stomach; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for years when kept dry[6][7].
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days[8]. Avoid freeze–thaw; aliquot if needed.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Reconstituted vials and opened bacteriostatic water should be discarded after 28 days[8].

How This Works

GHRP-2 (pralmorelin) is a Growth Hormone Releasing Peptide that binds to the ghrelin/GHS (Growth Hormone Secretagogue) receptor (GHS-R1a) on pituitary somatotroph cells and in the hypothalamus[1]. By activating these receptors, GHRP-2 triggers a potent pulse of GH release, independent of the usual GH-releasing hormone (GHRH) pathway. Research demonstrates GHRP-2 can stimulate GH even when GHRH action is impaired[11]. Unlike exogenous GH, GHRP-2 preserves natural pulsatile secretion patterns and works synergistically with endogenous GHRH[4].

Potential Benefits & Side Effects

Observations from preclinical and clinical literature.

  • Supports pulsatile GH release and may increase IGF-1 levels over time with consistent use[4].
  • May support improvements in body composition, recovery, and sleep quality when combined with appropriate lifestyle factors.
  • Transient increases in appetite (ghrelin receptor activation), cortisol, and prolactin have been observed in studies[2].
  • Receptor desensitization (tachyphylaxis) may occur with continuous daily use; cycling protocols may help maintain responsiveness[9][10].
  • Generally well tolerated; occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

  • Pair with a balanced, protein‑forward diet tailored to energy needs.
  • Combine resistance training and aerobic activity to reinforce metabolic adaptations.
  • Prioritize sleep and stress management to support adherence and recovery.
  • Inject on an empty stomach (2–3 hours post-meal) to maximize the GH response.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[12].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
  • Use fine-gauge needles (30 G or smaller) and small injection volumes to minimize discomfort[14].

Important Note

This content is for educational purposes only and is not medical advice.

References


  • Wikipedia
    — Pralmorelin (GHRP-2): peptide identity, mechanism of action, and ghrelin receptor agonism
    View Source

  • PubMed
    — Effects of GHRP-2 and hexarelin on GH, prolactin, ACTH, and cortisol levels in man
    View Source

  • PubMed
    — Diagnostic studies with IV and intranasal GHRP-2 in children of short stature
    View Source

  • PMC
    — Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum IGF-1 Levels
    View Source

  • Endocrine Reviews
    — Growth hormone secretion during sleep: timing and physiological significance
    View Source

  • Sigma-Aldrich (MilliporeSigma)
    — Peptide Handling and Storage Guidelines (lyophilized storage at −20 °C)
    View Source

  • GenScript
    — Peptide Storage and Handling Guidelines (freeze-thaw avoidance, aliquoting)
    View Source

  • CDC
    — Injection Safety: Multi-dose vial 28-day rule and safe injection practices
    View Source

  • PubMed
    — Five-day subcutaneous GHRP-2 treatment: response attenuation (tachyphylaxis) in healthy men
    View Source

  • Asian-Australas J. Anim. Sci.
    — Effect of twice-daily GHRP-2 in swine: GH peak attenuation by Day 10
    View Source

  • PMC
    — GH response to GHRP-2 in GH-deficient mice: GHRH-independent mechanism
    View Source

  • MedlinePlus
    — Subcutaneous Injections: site selection, angle technique, and sharps disposal
    View Source

  • OncoLink
    — How to Give a Subcutaneous Injection: technique and site rotation
    View Source

  • PMC
    — Subcutaneous Injection of Drugs: factors influencing pain and comfort
    View Source

  • Pure Lab Peptides
    — GHRP-2 (10 mg) product page (quality and batch documentation)
    View Source